 Neuroprotective Agents
"Neuroprotective Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
| Descriptor ID |
D018696
|
| MeSH Number(s) |
D27.505.696.706.548 D27.505.954.427.575
|
| Concept/Terms |
Neuroprotective Agents- Neuroprotective Agents
- Agents, Neuroprotective
- Neuroprotectants
- Neuroprotective Drugs
- Drugs, Neuroprotective
Neuroprotective Effect- Neuroprotective Effect
- Effect, Neuroprotective
- Neuroprotective Effects
- Effects, Neuroprotective
|
Below are MeSH descriptors whose meaning is more general than "Neuroprotective Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuroprotective Agents".
This graph shows the total number of publications written about "Neuroprotective Agents" by people in this website by year, and whether "Neuroprotective Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1997 | 1 | 2 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 3 | 0 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 2 | 3 | | 2006 | 3 | 0 | 3 | | 2007 | 5 | 0 | 5 | | 2008 | 3 | 0 | 3 | | 2009 | 4 | 2 | 6 | | 2010 | 8 | 0 | 8 | | 2011 | 7 | 2 | 9 | | 2012 | 5 | 0 | 5 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 2 | 4 | | 2015 | 2 | 4 | 6 | | 2016 | 4 | 0 | 4 | | 2017 | 3 | 0 | 3 | | 2018 | 5 | 2 | 7 | | 2019 | 2 | 0 | 2 | | 2020 | 2 | 2 | 4 | | 2021 | 3 | 0 | 3 | | 2022 | 1 | 0 | 1 | | 2024 | 3 | 0 | 3 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroprotective Agents" by people in Profiles.
-
Nguyen HQD, Nam MH, Vigh J, Brzezinski J, Duncan L, Park D. Co-delivery of neurotrophic factors and a zinc chelator substantially increases retinal ganglion cell survival and axon protection in the optic nerve crush model. Acta Biomater. 2025 Jul 01; 201:297-308.
-
Brown CN, Blaine RE, Barker CM, Coultrap SJ, Bayer KU. The neuroprotective ?-hydroxybutyrate analog 3-hydroxycyclopent-1-enecarboxylic acid does not directly affect CaMKIIa autophosphorylation at T286 or binding to GluN2B. Mol Pharmacol. 2025 Apr; 107(4):100029.
-
Johnson GA, Krishnamoorthy RR, Nagaraj RH, Stankowska DL. A Neuroprotective Peptide Modulates Retinal cAMP Response Element-Binding Protein (CREB), Synapsin I (SYN1), and Growth-Associated Protein 43 (GAP43) in Rats with Silicone Oil-Induced Ocular Hypertension. Biomolecules. 2025 Feb 03; 15(2).
-
Latham AS, Rocha SM, McDermott CP, Reigan P, Slayden RA, Tjalkens RB. Neuroprotective efficacy of the glucocorticoid receptor modulator PT150 in the rotenone mouse model of Parkinson's disease. Neurotoxicology. 2024 Jul; 103:320-334.
-
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol. 2024 Jul; 23(7):687-699.
-
Gurrea-Rubio M, Wang Q, Mills EA, Wu Q, Pitt D, Tsou PS, Fox DA, Mao-Draayer Y. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NF?B and Mitochondrial Pathways. Int J Mol Sci. 2024 Feb 20; 25(5).
-
Kompella UB. 2021 JOPT Award in Science: Dr. Bärbel Rohrer's Research on Mitochondria-Targeted Neuroprotective Drugs. J Ocul Pharmacol Ther. 2022 11; 38(9):591.
-
Neumann NR, Thompson DC, Vasiliou V. AMPK activators for the prevention and treatment of neurodegenerative diseases. Expert Opin Drug Metab Toxicol. 2021 Oct; 17(10):1199-1210.
-
Polutchko SK, Glime GNE, Demmig-Adams B. Synergistic Action of Membrane-Bound and Water-Soluble Antioxidants in Neuroprotection. Molecules. 2021 Sep 04; 26(17).
-
Hermes DJ, Yadav-Samudrala BJ, Xu C, Paniccia JE, Meeker RB, Armstrong ML, Reisdorph N, Cravatt BF, Mackie K, Lichtman AH, Ignatowska-Jankowska BM, Lysle DT, Fitting S. GPR18 drives FAAH inhibition-induced neuroprotection against HIV-1 Tat-induced neurodegeneration. Exp Neurol. 2021 07; 341:113699.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|